Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The early developments of preeclampsia drugs.

Literature DB >> 27253272

The early developments of preeclampsia drugs.

Maged M Costantine¹, Cande V Ananth².

Abstract

Entities: Chemical Disease Gene Species

Keywords: Angiogenic imbalance; endothelial dysfunction; pravastatin; preeclampsia; pregnancy; statins

Mesh：

Year: 2016 PMID： 27253272 PMCID： PMC4979221 DOI： 10.1080/13543784.2016.1196185

Source DB: PubMed Journal: Expert Opin Investig Drugs ISSN： 1354-3784 Impact factor: 6.206

× No keyword cloud information.

18 in total

1. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Authors: Keiichi Kumasawa; Masahito Ikawa; Hiroyasu Kidoya; Hidetoshi Hasuwa; Tomoko Saito-Fujita; Yuka Morioka; Nobuyuki Takakura; Tadashi Kimura; Masaru Okabe
Journal: Proc Natl Acad Sci U S A Date: 2010-12-27 Impact factor: 11.205

Review 2. Risks of statin use during pregnancy: a systematic review.

Authors: Aleksey Kazmin; Facundo Garcia-Bournissen; Gideon Koren
Journal: J Obstet Gynaecol Can Date: 2007-11

Review 3. Redefining preeclampsia using placenta-derived biomarkers.

Authors: Anne Cathrine Staff; Samantha J Benton; Peter von Dadelszen; James M Roberts; Robert N Taylor; Robert W Powers; D Stephen Charnock-Jones; Christopher W G Redman
Journal: Hypertension Date: 2013-03-04 Impact factor: 10.190

4. Ischemic placental disease: a unifying concept for preeclampsia, intrauterine growth restriction, and placental abruption.

Authors: Cande V Ananth
Journal: Semin Perinatol Date: 2014-04 Impact factor: 3.300

5. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial.

Authors: Maged M Costantine; Kirsten Cleary; Mary F Hebert; Mahmoud S Ahmed; Linda M Brown; Zhaoxia Ren; Thomas R Easterling; David M Haas; Laura S Haneline; Steve N Caritis; Raman Venkataramanan; Holly West; Mary D'Alton; Gary Hankins
Journal: Am J Obstet Gynecol Date: 2015-12-23 Impact factor: 8.661

Review 6. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors: T Hatanaka
Journal: Clin Pharmacokinet Date: 2000-12 Impact factor: 6.447

7. The two stage model of preeclampsia: variations on the theme.

Authors: J M Roberts; C A Hubel
Journal: Placenta Date: 2008-12-13 Impact factor: 3.481

8. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion.

Authors: Stephen Tong; Tu'uhevaha J Kaitu'u-Lino; Kenji Onda; Sally Beard; Roxanne Hastie; Natalie K Binder; Cathy Cluver; Laura Tuohey; Clare Whitehead; Fiona Brownfoot; Manarangi De Silva; Natalie J Hannan
Journal: Hypertension Date: 2015-08-31 Impact factor: 10.190

The early developments of preeclampsia drugs.

1. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.

Review 2. Risks of statin use during pregnancy: a systematic review.

Review 3. Redefining preeclampsia using placenta-derived biomarkers.

4. Ischemic placental disease: a unifying concept for preeclampsia, intrauterine growth restriction, and placental abruption.

5. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial.

Review 6. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

7. The two stage model of preeclampsia: variations on the theme.

8. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion.

9. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1.

Review 10. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.

Review 1. Novel Interventions for the Prevention of Preeclampsia.

2. Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

Review 3. An Overview of Obesity, Cholesterol, and Systemic Inflammation in Preeclampsia.